US Bankruptcy Chapter 11 Insolvency SEC Filings — July 20, 2026

Chapter 11 filing with court-approved bidding procedures for substantially all assets; bid deadline August 4, 2026, auction August 10, 2026 [BEARISH for equity, OPPORTUNISTIC for distressed debt]

Nasdaq Hearings Panel denied listing continuation; stock now trades on OTCID Basic Market under SGMOQ, indicating zero equity value recovery

No forward-looking statements or guidance in filing, confirming no operational future; management has abandoned turnaround efforts

No insider trading activity reported, consistent with bankruptcy where insiders typically lose all equity stakes

No capital allocation actions (dividends, buybacks) as company is in liquidation mode

Asset sale timeline is compressed (bid deadline in ~2 weeks), forcing potential fire-sale pricing [BEARISH for creditors, OPPORTUNISTIC for buyers]

No financial ratios or operational metrics disclosed, typical for a bankruptcy filing focused on legal procedures

Sentiment is negative with materiality 9/10, confirming this is a high-impact event with no positive catalysts

Company is selling substantially all assets; no plan to appeal Nasdaq delisting, indicating management sees no future

Bid deadline August 4, 2026, is only ~2 weeks away; compressed timeline may lead to inadequate bids

No disclosed minimum bid or asset valuation; creditors face uncertainty on recovery rates

Stock moved to OTCID Basic Market; liquidity is near zero, making equity positions virtually worthless

Absence of insider buying or selling is typical in bankruptcy, but signals no confidence in any recovery

Filing contains no revenue, cash flow, or operational forecasts; investors have no basis for valuation

Bankruptcy court approval required for sale; any objections could delay or derail the process

Other distressed biotech assets may compete for buyer attention, reducing bid interest

For specialized distressed investors, the forced asset sale could yield valuable gene therapy IP at fire-sale prices; bid deadline August 4

Senior secured creditors may recover significant value if assets are sold; monitor bidding process for recovery estimates

If multiple qualified bids emerge by August 4, auction on August 10 could drive up asset price; watch for bidder interest

For active traders, the OTC stock (SGMOQ) may still trade with volatility; short sellers could profit from continued decline

This filing provides a template for other distressed biotechs; investors can study the process to anticipate similar events

Unlike pre-bankruptcy periods where insiders may dump shares, the filing shows no insider activity, removing one source of downward pressure

Sangamo's Chapter 11 filing reflects ongoing distress in the biotech sector, where cash-burning companies with failed clinical trials face liquidation; this is the latest in a trend of small-cap biotech bankruptcies

The compressed timeline (bid deadline in 2 weeks) is typical for Chapter 11 asset sales; buyers can acquire IP at distressed valuations, but sellers risk inadequate bids

The denial of listing continuation and move to OTC is a common pattern for bankrupt biotechs; equity holders are wiped out, and trading moves to illiquid markets

Unlike some Chapter 11 filings that aim for reorganization, Sangamo's sale of substantially all assets signals a liquidation, not a restructuring; this is a growing trend for cash-strapped biotechs

August 4, 2026, at 5:00 p.m. ET; watch for number and quality of qualified bids to gauge asset value

August 10, 2026, at 10:00 a.m. ET; if multiple bids, auction could drive up price; monitor for winning bidder and price

Any objections to bidding procedures or sale could delay process; watch docket for new filings

Monitor SGMOQ for any unusual volume or price movements ahead of bid deadline; could signal insider or creditor activity

Watch for any creditor committee formation or objections that could alter sale terms

After auction, court approval and closing timeline will determine when creditors are paid; monitor for recovery estimates